MWPCG
SUPN icon

Measured Wealth Private Client Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Measured Wealth Private Client Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,941
Closed -$287K – 134
2020
Q1 		$287K Buy
15,941
+3,725
+30% +$78.3K 0.22% 65
2019
Q4 		$290K Buy
+12,216
New +$297K 0.19% 75

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Measured Wealth Private Client Group's SUPN Position: Q2 2020 in Review

Measured Wealth Private Client Group sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 15,941 shares — an estimated $287K sold.

Measured Wealth Private Client Group first reported a position in SUPN in Q4 2019 and held it in 2 quarters. The position peaked at $290K in Q4 2019. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

  • Measured Wealth Private Client Group reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Measured Wealth Private Client Group sold 15,941 Supernus Pharmaceuticals shares in Q2 2020, an estimated $287K.
  • Measured Wealth Private Client Group first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Measured Wealth Private Client Group's Supernus Pharmaceuticals position peaked at $290K in Q4 2019.
  • 218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2020, filed 3 Aug 2020.